Corcept Therapeutics CORT Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $9.64M.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's total debt?
- Corcept Therapeutics (CORT) reported total debt of $9.64M in Q1 2026.
- How has Corcept Therapeutics's total debt changed year-over-year?
- Corcept Therapeutics's total debt increased by 41.0% year-over-year, from $6.84M to $9.64M.
- What is the long-term trend for Corcept Therapeutics's total debt?
- Over 5 years (2020 to 2025), Corcept Therapeutics's total debt has grown at a 19.1% compound annual growth rate (CAGR), from $2.55M to $6.11M.
- What does total debt mean?
- The total amount of money a company owes to lenders, banks, and lessors.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may heighten insolvency risk, while a decrease indicates deleveraging and improved balance sheet health.
- How does total debt compare across companies?
- Biopharmaceutical companies often maintain low debt levels to preserve cash for R&D, though levels vary significantly based on the stage of clinical development and commercial maturity.